Dare Bioscience (DARE) Stock: Buy, Sell, or Hold?
DARE - Dare Bioscience, Inc. Common Stock
$0.71
0.00 (0.13%)
â˛
5d:
-1.0%
30d:
-50.97%
90d:
-65.22%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When DARE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: DARE is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: DARE is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: DARE is currently trading at $0.71, which is considered slightly low relative to its 30-day fair value range of $0.65 to $1.20. From a valuation perspective, the stock is trading at a discount (Forward PE: -1.7) compared to its historical average (3.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, DARE is in a strong downtrend. The price is currently testing key support at $0.69. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $8.33 (+1080.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, DARE is in a strong downtrend. The price is currently testing key support at $0.69. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $8.33 (+1080.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$0.65 -
$1.20
Company Quality Score
47/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: Trading 1080.4% below Wall St target ($8.33)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 47/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.65 -
$1.20
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$0.69
Resistance Level
$0.82
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.70
Wall Street Target
$8.33
(+1080.4%)
Revenue Growth (YoY)
499.6%
PE vs Historical
-1.7 vs 3.6
CHEAP
Share & Embed Analysis
Last updated: September 13, 2026 10:28 AM ET
Data refreshes hourly during market hours. Next update: 11:28 AM
Data refreshes hourly during market hours. Next update: 11:28 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DARE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 32 SELL |
|
REGN
Regeneron PharmaceuticalâĻ |
STRONG BUY
25 analysts |
$849 | 50 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 43 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$290 | 59 HOLD |
|
MLTX
MoonLake ImmunotherapeutâĻ |
STRONG BUY
16 analysts |
$29 | 41 HOLD |
